New hope for Alzheimer's: safety trial of Add-On therapy begins
NCT ID NCT07212062
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding an experimental drug (X/T+X-EC) to standard Alzheimer's treatment (lecanemab) is safe and tolerable. About 60 adults with Alzheimer's will receive either the drug or a placebo for 24 weeks. The main goal is to check for side effects, not to measure if the drug improves symptoms.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMERS DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Real-World data uncover hidden risks of the Alzheimer's drug LEQEMBI?
- Could a diabetes drug tame Alzheimer's inflammation?
- Nasal spray could tame brain inflammation in early Alzheimer's
- New drug aims to stop Alzheimer's before it starts in gene carriers
- Scientists hunt for molecular proof that music helps Alzheimer's patients
- Blood test aimed to speed up Alzheimer's diagnosis, but study was canceled